Page 78 - GTM-1-1

Global Translational Medicine ctDNA in management of patients with NSCLC

12. Chen KZ, Lou F, Yang F, et al., 2016, Circulating tumor DNA https://doi.org/10.1038/nature05329
detection in early-stage non-small cell lung cancer patients 23. Douville C, Springer S, Kinde I, et al., 2018, Detection of
by targeted sequencing. Sci Rep, 6: 31985. aneuploidy in patients with cancer through amplification
https://doi.org/10.1038/srep31985 of long interspersed nucleotide elements (LINEs). Proc Natl
Acad Sci U S A, 115(8): 1871–1876.
13. Jiao XD, Ding LR, Zhang CT, et al., 2021, Serum tumor
markers for the prediction of concordance between genomic https://doi.org/10.1073/pnas.1717846115
profiles from liquid and tissue biopsy in patients with 24. Cristiano S, Leal A, Phallen J, et al., 2019, Genome-wide cell-
advanced lung adenocarcinoma. Transl Lung Cancer Res, free DNA fragmentation in patients with cancer. Nature,
10(7): 3236–3250. 570(7761): 385–389.
https://doi.org/10.21037/tlcr-21-543 https://doi.org/10.1038/s41586-019-1272-6
14. Scherer F, 2020, Capturing tumor heterogeneity and clonal 25. Ulz P, Perakis S, Zhou Q, et al., 2019, Inference of
evolution by circulating tumor DNA profiling. Recent Results transcription factor binding from cell-free DNA enables
Cancer Res, 215: 213–230. tumor subtype prediction and early detection. Nat Commun,
https://doi.org/10.1007 / 978-3-030-26439-0_11 10(1): 4666.
15. Abbosh C, Birkbak NJ, Wilson GA, et al., 2017, Phylogenetic https://doi.org/10.1038/s41467-019-12714-4
ctDNA analysis depicts early-stage lung cancer evolution. 26. Ansari J, Shackelford RE, El-Osta H, 2016, Epigenetics in
Nature, 545(7655): 446–451. non-small cell lung cancer: from basics to therapeutics.
https://doi.org/10.1038/nature22364 Transl Lung Cancer Res, 5(2): 155–171.
16. Chen K, Kang G, Zhao H, et al., 2019, Liquid biopsy in newly https://doi.org/10.21037/tlcr.2016.02.02
diagnosed patients with locoregional (I-IIIA) non-small cell 27. Lu F, Zhang HT, 2011, DNA methylation and nonsmall cell
lung cancer. Expert Rev Mol Diagn, 19(5): 419–427. lung cancer. Anat Rec (Hoboken), 294(11): 1787–1795.
https://doi.org/10.1080 / 14737159.2019.1599717 28. Bergman Y, Cedar H, 2013, DNA methylation dynamics in
17. Spindler KL, Pallisgaard N, Vogelius I, et al., 2012, health and disease. Nat Struct Mol Biol, 20(3): 274–281.
Quantitative cell-free DNA, KRAS, and BRAF mutations https://doi.org/10.1038/nsmb.2518
in plasma from patients with metastatic colorectal cancer 29. Lianidou E, 2021, Detection and relevance of epigenetic
during treatment with cetuximab and irinotecan. Clin markers on ctDNA: Recent advances and future outlook.
Cancer Res, 18(4): 1177–1185.
Mol Oncol, 15(6): 1683–1700.
https://doi.org/10.1158 / 1078-0432.CCR-11-0564
https://doi.org/10.1002 / 1878-0261.12978
18. Gormally E, Caboux E, Vineis P, et al., 2007, Circulating free 30. Kurdyukov S, Bullock M, 2016, DNA methylation analysis:
DNA in plasma or serum as biomarker of carcinogenesis: Choosing the right method. Biology (Basel), 5(1): 3.
Practical aspects and biological significance. Mutat Res,
635(2-3): 105–117. https://doi.org/10.3390/biology5010003
https://doi.org/10.1016/j.mrrev.2006.11.002 31. Li S, Tollefsbol TO, 2021, DNA methylation methods: Global
DNA methylation and methylomic analyses. Methods,
19. To EW, Chan KC, Leung SF, et al., 2003, Rapid clearance 187: 28–43.
of plasma Epstein-Barr virus DNA after surgical treatment
of nasopharyngeal carcinoma. Clin Cancer Res, 9(9): https://doi.org/10.1016/j.ymeth.2020.10.002
3254–3259. 32. Bajbouj K, Al-Ali A, Ramakrishnan RK, et al., 2021, Histone
20. Keller L, Belloum Y, Wikman H, et al., 2021, Clinical modification in NSCLC: Molecular mechanisms and
relevance of blood-based ctDNA analysis: Mutation therapeutic targets. Int J Mol Sci, 22(21): 11701.
detection and beyond. Br J Cancer, 124(2): 345–358. https://doi.org/10.3390/ijms222111701
https://doi.org/10.1038/s41416-020-01047-5 33. Friedman RC, Farh KK, Burge CB, et al., 2009, Most
21. Adalsteinsson VA, Ha G, Freeman SS, et al., 2017, Scalable mammalian mRNAs are conserved targets of microRNAs.
whole-exome sequencing of cell-free DNA reveals high Genome Res, 19(1): 92–105.
concordance with metastatic tumors. Nat Commun, 8(1): 1324. https://doi.org/10.1101/gr.082701.108
https://doi.org/10.1038/s41467-017-00965-y 34. Vos PD, Leedman PJ, Filipovska A, et al., 2019, Modulation
22. Redon R, Ishikawa S, Fitch KR, et al., 2006, Global variation of miRNA function by natural and synthetic RNA-binding
in copy number in the human genome. Nature, 444(7118): proteins in cancer. Cell Mol Life Sci, 76(19): 3745–3752.
444–454. https://doi.org/10.1007/s00018-019-03163-9

Volume 1 Issue 1 (2022) 11 https://doi.org/10.36922/gtm.v1i1.96